Eliglustat: Difference between revisions

Eliglustat
	Adult Indications & Dosage
	Pediatric Indications & Dosage
	Contraindications
	Warnings & Precautions
	Adverse Reactions
	Drug Interactions
	Use in Specific Populations
	Administration & Monitoring
	Overdosage
	Pharmacology
	Clinical Studies
	How Supplied
	Images
	Patient Counseling Information
	Precautions with Alcohol
	Brand Names
	Look-Alike Names

VisualWikitext

Revision as of 16:43, 18 February 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Kiran Singh, M.D. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Eliglustat is a {{{drugClass}}} that is FDA approved for the treatment of {{{indication}}}. Common adverse reactions include .

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

CERDELGA is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1) who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test.

Limitations of Use:

Patients who are CYP2D6 ultra-rapid metabolizers (URMs) may not achieve adequate concentrations of CERDELGA to achieve a therapeutic effect . A specific dosage cannot be recommended for those patients whose CYP2D6 genotype cannot be determined (indeterminate metabolizers).

Dosage

Patient Selection

Select patients with Gaucher disease type 1 based on their CYP2D6 metabolizer status. It is recommended patient genotypes be established using an FDA-cleared test for determining CYP2D6 genotype.

Recommended Adult Dosage

The recommended dosage of CERDELGA is 84 mg twice daily in CYP2D6 EMs and IMs. The recommended dosage in CYP2D6 PMs is 84 mg once daily; appropriate adverse event monitoring is recommended. The predicted exposures with 84 mg once daily in patients who are CYP2D6 PMs are expected to be similar to exposures observed with 84 mg twice daily in CYP2D6 IMs.

Some inhibitors of CYP2D6 and CYP3A are contraindicated with CERDELGA depending on the patient's metabolizer status [see CONTRAINDICATIONS (4)]. Co-administration of CERDELGA with other CYP2D6 and CYP3A inhibitors may require dosage adjustment depending on the patient's CYP2D6 metabolizer status to reduce the risk of potentially significant adverse reactions.

Reduce the dosage of CERDELGA to 84 mg once daily for:

CYP2D6 EMs and IMs taking strong or moderate CYP2D6 inhibitors
CYP2D6 EMs taking strong or moderate CYP3A inhibitors

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Eliglustat in adult patients.

Non–Guideline-Supported Use

Condition1

There is limited information regarding Off-Label Non–Guideline-Supported Use of Eliglustat in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding FDA-Labeled Use of Eliglustat in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Eliglustat in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Eliglustat in pediatric patients.

Contraindications

There is limited information regarding Eliglustat Contraindications in the drug label.

Warnings

There is limited information regarding Eliglustat Warnings' in the drug label.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Eliglustat in the drug label.

Cardiovascular

Digestive

Endocrine

Hematologic and Lymphatic

Metabolic and Nutritional

Musculoskeletal

Neurologic

Respiratory

Skin and Hypersensitivy Reactions

Special Senses

Urogenital

Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Eliglustat in the drug label.

Cardiovascular

Digestive

Endocrine

Hematologic and Lymphatic

Metabolic and Nutritional

Musculoskeletal

Neurologic

Respiratory

Skin and Hypersensitivy Reactions

Special Senses

Urogenital

Miscellaneous

Drug Interactions

There is limited information regarding Eliglustat Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

Pregnancy Category (AUS):

Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Eliglustat in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Eliglustat during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Eliglustat with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Eliglustat with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Eliglustat with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Eliglustat with respect to specific gender populations.

Race

There is no FDA guidance on the use of Eliglustat with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Eliglustat in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Eliglustat in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Eliglustat in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Eliglustat in patients who are immunocompromised.

Administration and Monitoring

Administration

Oral

Intravenous

Monitoring

There is limited information regarding Monitoring of Eliglustat in the drug label.

Description

IV Compatibility

There is limited information regarding IV Compatibility of Eliglustat in the drug label.

Overdosage

There is limited information regarding Chronic Overdose of Eliglustat in the drug label.

Pharmacology

There is limited information regarding Eliglustat Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Eliglustat Mechanism of Action in the drug label.

Structure

There is limited information regarding Eliglustat Structure in the drug label.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Eliglustat in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Eliglustat in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Eliglustat in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Eliglustat in the drug label.

How Supplied

Storage

There is limited information regarding Eliglustat Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Eliglustat |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Eliglustat |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Eliglustat in the drug label.

Precautions with Alcohol

Alcohol-Eliglustat interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

{{#subobject:

 |Page Name=Eliglustat
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Eliglustat
 |Label Name=Eliglustat11.png

}}

{{#subobject:

 |Label Page=Eliglustat
 |Label Name=Eliglustat11.png

}}

@@ Line 2: / Line 2: @@
 |authorTag={{KS}}
 |aOrAn=a
-|hasBlackBoxWarning=Yes
+|indicationType=treatment
 |adverseReactions=<!--Black Box Warning-->
 |blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
@@ Line 20: / Line 20: @@
 A specific dosage cannot be recommended for those patients whose CYP2D6 genotype cannot be determined (indeterminate metabolizers).
+==Dosage==
-|offLabelAdultGuideSupport======Condition1=====
+'''Patient Selection'''
-* Developed by:
+* Select patients with Gaucher disease type 1 based on their CYP2D6 metabolizer status. It is recommended patient genotypes be established using an FDA-cleared test for determining CYP2D6 genotype.
-* Class of Recommendation:
+'''Recommended Adult Dosage'''
-* Strength of Evidence:
+* The recommended dosage of CERDELGA is 84 mg twice daily in CYP2D6 EMs and IMs. The recommended dosage in CYP2D6 PMs is 84 mg once daily; appropriate adverse event monitoring is recommended. The predicted exposures with 84 mg once daily in patients who are CYP2D6 PMs are expected to be similar to exposures observed with 84 mg twice daily in CYP2D6 IMs.
-* Dosing Information
+* Some inhibitors of CYP2D6 and CYP3A are contraindicated with CERDELGA depending on the patient's metabolizer status [see CONTRAINDICATIONS (4)]. Co-administration of CERDELGA with other CYP2D6 and CYP3A inhibitors may require dosage adjustment depending on the patient's CYP2D6 metabolizer status to reduce the risk of potentially significant adverse reactions.
-:* Dosage
+* Reduce the dosage of CERDELGA to 84 mg once daily for:
-=====Condition2=====
+:* CYP2D6 EMs and IMs taking strong or moderate CYP2D6 inhibitors
+:* CYP2D6 EMs taking strong or moderate CYP3A inhibitors
+|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
-There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
-<!--Non–Guideline-Supported Use (Adult)-->
 |offLabelAdultNoGuideSupport======Condition1=====
+There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
-* Dosing Information
-:* Dosage
-=====Condition2=====
-There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
-<!--Pediatric Indications and Dosage-->
 <!--FDA-Labeled Indications and Dosage (Pediatric)-->
-|fdaLIADPed======Condition1=====
+|fdaLIADPed=There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
-* Dosing Information
-:* Dosage
-=====Condition2=====
-There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
-<!--Off-Label Use and Dosage (Pediatric)-->
-<!--Guideline-Supported Use (Pediatric)-->
-|offLabelPedGuideSupport======Condition1=====
-* Developed by:
-* Class of Recommendation:
-* Strength of Evidence:
-* Dosing Information
-:* Dosage
-=====Condition2=====
+|offLabelPedGuideSupport=
 There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
-<!--Non–Guideline-Supported Use (Pediatric)-->
-|offLabelPedNoGuideSupport======Condition1=====
-* Dosing Information
+|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
-:* Dosage
-=====Condition2=====
+|warnings=
-There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
-<!--Contraindications-->
+|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
-|contraindications=* Condition1
-<!--Warnings-->
-|warnings=* Description
-====Precautions====
-* Description
-<!--Adverse Reactions-->
-<!--Clinical Trials Experience-->
-|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
-=====Body as a Whole=====
@@ Line 173: / Line 128: @@
 |postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
-=====Body as a Whole=====
@@ Line 226: / Line 180: @@
 <!--Drug Interactions-->
-|drugInteractions=* Drug
+|useInPregnancyFDA=*
-:* Description
-<!--Use in Specific Populations-->
-|useInPregnancyFDA=* '''Pregnancy Category'''
 |useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
@@ Line 245: / Line 195: @@
 |useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
-<!--Administration and Monitoring-->
 |administration=* Oral
@@ Line 256: / Line 206: @@
 |IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
-<!--Overdosage-->
-|overdose====Acute Overdose===
-====Signs and Symptoms====
-* Description
-====Management====
-* Description
-===Chronic Overdose===
+|overdose=There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
-There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
-<!--Pharmacology-->
 <!--Drug box 2-->
-|drugBox=<!--Mechanism of Action-->
+|structure=
-|mechAction=*
-<!--Structure-->
-|structure=*
-: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
+|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
-<!--Pharmacodynamics-->
-|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
-<!--Pharmacokinetics-->
 |PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
-<!--Nonclinical Toxicology-->
 |nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
-<!--Clinical Studies-->
 |clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
-<!--How Supplied-->
 |howSupplied=*
-|packLabel=<!--Patient Counseling Information-->
 |fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
-<!--Precautions with Alcohol-->
 |alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
-<!--Brand Names-->
-|brandNames=* ®<ref>{{Cite web | title =  | url = }}</ref>
-<!--Look-Alike Drug Names-->
-|lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>
-<!--Drug Shortage Status-->
+|brandNames=*
+|lookAlike=*
 |drugShortage=
 }}